Global Adult Vaccine vs. Pediatric Vaccine Market Share
Download full Report: http://www.renub.com/global-vaccines-market-and-forecast-14-vaccines-market-number-of-people-immunized-doses-of-vaccines-administered-1200-p.php Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is having a dominant market share compared to Adult vaccines market. By 2022 Pediatric vaccines market share will be double the size of adult vaccines market share. Worldwide the number of infants immunized by influenza vaccines remain considerably low than that of adults immunized in year 2017. While the number of Rotavirus doses administered in infants is forecast to increase over the years and reach nearly 15 Million by the year 2022. Adult Vaccine Market Share Analysis Out of the total 9 Adult vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the adult vaccine market in 2017.
Download full Report: http://www.renub.com/global-vaccines-market-and-forecast-14-vaccines-market-number-of-people-immunized-doses-of-vaccines-administered-1200-p.php
Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is having a dominant market share compared to Adult vaccines market. By 2022 Pediatric vaccines market share will be double the size of adult vaccines market share. Worldwide the number of infants immunized by influenza vaccines remain considerably low than that of adults immunized in year 2017. While the number of Rotavirus doses administered in infants is forecast to increase over the years and reach nearly 15 Million by the year 2022.
Adult Vaccine Market Share Analysis
Out of the total 9 Adult vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the adult vaccine market in 2017.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast (14 <strong>Vaccine</strong>s <strong>Market</strong>, Number of People Immunized Doses<br />
of <strong>Vaccine</strong>s Administered)<br />
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast<br />
Free 10% Customization in this Report<br />
Analyst View:<br />
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> to reach US$ 60 Billion by the year 2022. <strong>Pediatric</strong> vaccines market is<br />
having a dominant market share compared to <strong>Adult</strong> vaccines market.<br />
Report Title:<br />
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast (14 <strong>Vaccine</strong>s <strong>Market</strong>, Number of People Immunized<br />
Doses of <strong>Vaccine</strong>s Administered)<br />
Download full Report:<br />
http://www.renub.com/global-vaccines-market-and-forecast-14-vaccines-market-numberof-people-immunized-doses-of-vaccines-administered-1200-p.php<br />
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> to reach US$ 60 Billion by the year 2022. <strong>Pediatric</strong> vaccines market is<br />
having a dominant market share compared to <strong>Adult</strong> vaccines market. By 2022 <strong>Pediatric</strong><br />
vaccines market share will be double the size of adult vaccines market share. Worldwide the<br />
number of infants immunized by influenza vaccines remain considerably low than that of adults<br />
immunized in year 2017. While the number of Rotavirus doses administered in infants is<br />
forecast to increase over the years and reach nearly 15 Million by the year 2022.<br />
<strong>Adult</strong> <strong>Vaccine</strong> <strong>Market</strong> <strong>Share</strong> Analysis<br />
Out of the total 9 <strong>Adult</strong> vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal,<br />
Meningococcal, Hepatitis, TdaP, Travel) studied in the report Influenza vaccines dominates the<br />
adult vaccine market in 2017.<br />
<strong>Pediatric</strong> <strong>Vaccine</strong> <strong>Market</strong> <strong>Share</strong> Analysis<br />
Our analysis found that in year 2017; Pneumococcal and Combination vaccine together accounts<br />
for nearly 50% of the pediatric vaccine market share. Other <strong>Pediatric</strong> vaccines market studied<br />
in the report are as follows: Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap,<br />
Haemophilus Influenzae Type b(Hib), Combos, Polio, Rotavirus, Varicella.<br />
© Renub Research LLP Page 1 of 3
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast (14 <strong>Vaccine</strong>s <strong>Market</strong>, Number of People Immunized Doses<br />
of <strong>Vaccine</strong>s Administered)<br />
In 2017 Combos <strong>Vaccine</strong>s will control the Immunization <strong>Share</strong><br />
For the year 2017; Combos (Combination <strong>Vaccine</strong>s) has the maximum immunization share<br />
among all pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap,<br />
Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) studied in the report as they<br />
protect against more ailments in single shot, people preferring to get combination vaccine<br />
instead of a specific vaccine.<br />
Administration of <strong>Vaccine</strong> Doses<br />
Our analysis found that there is a consistent surge in the number of Pneumococcal and<br />
Meningococcal vaccine doses administration in future due to the rising concern against the lifethreatening<br />
vaccine-preventable diseases around the world.<br />
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast (14 <strong>Vaccine</strong>s <strong>Market</strong>, Number of People Immunized<br />
Doses of <strong>Vaccine</strong>s Administered) is the 8 th edition of market research report published<br />
by Renub Research on <strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong>. This is a 318 page report with 193 Figures and<br />
44 Tables provides data of <strong>Global</strong> <strong>Vaccine</strong> <strong>Market</strong> (<strong>Adult</strong> & <strong>Pediatric</strong>s), People Immunized,<br />
Number of <strong>Vaccine</strong> Doses Administered (Disease wise) & Key Players. <strong>Vaccine</strong> has been<br />
extensively studied from 3 major points, and further sub-divided into 2 more points:<br />
1. World <strong>Vaccine</strong>s (Disease wise) <strong>Market</strong> & Forecast (2011 – 2022)<br />
a. <strong>Adult</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast<br />
b. <strong>Pediatric</strong>s <strong>Vaccine</strong>s <strong>Market</strong> & Forecast<br />
2. People Immunized (Disease wise) & Forecast (2011 – 2022)<br />
a. <strong>Adult</strong> Immunized & Forecast<br />
b. <strong>Pediatric</strong> (Infants) Immunized & Forecast<br />
3. Doses of <strong>Vaccine</strong>s Administered (Disease wise) & Forecast (2011 – 2022)<br />
a. Doses of vaccines administered in <strong>Adult</strong>s & Forecast<br />
b. Doses of vaccines administered in <strong>Pediatric</strong> (Infants) & Forecast<br />
14 <strong>Vaccine</strong>s Studied in the Report are as Follows:<br />
1. Influenza<br />
2. Cervical Cancer<br />
3. Zoster (Shingles)<br />
4. MMR (Measles, Mumps, and Rubella)<br />
5. Pneumonia<br />
6. Meningitis<br />
7. Hepatitis<br />
8. Tap (Diphtheria, Tetanus, Pertussis)<br />
9. Haemophilus influenzae type B<br />
© Renub Research LLP Page 2 of 3
<strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast (14 <strong>Vaccine</strong>s <strong>Market</strong>, Number of People Immunized Doses<br />
10. Polio<br />
11. Rotavirus<br />
12. Varicella<br />
13. Combination <strong>Vaccine</strong><br />
14. Travel & Miscellaneous <strong>Vaccine</strong><br />
of <strong>Vaccine</strong>s Administered)<br />
Why This Report a Compulsory Buy!<br />
<br />
<br />
<br />
<br />
This report offers complete analysis of Disease wise <strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> & Forecast<br />
(2011 – 2022).<br />
This report offers segmented analysis of Disease wise <strong>Global</strong> <strong>Vaccine</strong>s <strong>Market</strong> into two<br />
segments:<br />
o <strong>Adult</strong> <strong>Vaccine</strong>s (Disease wise) <strong>Market</strong> &Forecast<br />
o <strong>Pediatric</strong> (Infant) <strong>Vaccine</strong>s (Disease wise) <strong>Market</strong> &Forecast<br />
This report offers extensive analysis of the number of people Immunized and Number of<br />
<strong>Vaccine</strong>s Doses Administered & Forecast (2011 – 2022) by <strong>Adult</strong> & <strong>Pediatric</strong> (Infant).<br />
This report offers widespread analysis on <strong>Vaccine</strong> Key Players (Worldwide) & Forecast<br />
(2011 – 2022)<br />
<strong>Vaccine</strong>s Report:<br />
http://www.renub.com/vaccines-12-c.php<br />
Renub Research - North America<br />
Rajat Gupta<br />
225 Kristie Ln, Roswell<br />
Georgia 30076, United States<br />
Tel: +1-678-302-0700<br />
Email: info@renub.com<br />
www.renub.com<br />
Renub Research - Asia<br />
Ankit Mishra<br />
C – 86, Sector – 10<br />
Noida 201301, India<br />
Tel: +91-120-421-9822<br />
Email: info@renub.com<br />
www.renub.com<br />
© Renub Research LLP Page 3 of 3
Change language